These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 3480796)
1. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin. Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G Drugs Exp Clin Res; 1987; 13(9):555-61. PubMed ID: 3480796 [TBL] [Abstract][Full Text] [Related]
2. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin. Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153 [TBL] [Abstract][Full Text] [Related]
3. Susceptibility in vitro of gram-positive aerobe and anaerobe bacteria to ofloxacin. Debbia E; Mannelli S; Gianrossi G; Schito GC Drugs Exp Clin Res; 1987; 13(4):213-7. PubMed ID: 3304918 [TBL] [Abstract][Full Text] [Related]
4. Ofloxacin: antibacterial activity, induction of resistance and killing curves. Husson MO; Izard D; Bryskier A; Leclerc H Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates. Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230 [TBL] [Abstract][Full Text] [Related]
6. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins]. Croize J; Le Noc P; Bryskier A; Robert J Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics. Debbia E; Schito GC; Nicoletti G; Speciale A Chemioterapia; 1987 Oct; 6(5):319-23. PubMed ID: 3480779 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808 [TBL] [Abstract][Full Text] [Related]
9. Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates. Qadri SM; Lee G; Brodie L Drugs Exp Clin Res; 1989; 15(8):349-53. PubMed ID: 2598776 [TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates]. Mancini C; Brenciaglia MI; Ghezzi MC; Giordano A; Nazzari C; Cipriani P Boll Ist Sieroter Milan; 1985; 64(4):289-93. PubMed ID: 3935135 [TBL] [Abstract][Full Text] [Related]
11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ; Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS; Jones RN; Dowzicky MJ; Fritsche TR Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [TBL] [Abstract][Full Text] [Related]
14. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)]. Grimm H Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655 [TBL] [Abstract][Full Text] [Related]
15. Microbiological characterization of dactimicin: antibacterial activity towards gram-positive and gram-negative bacteria. Stefani S; Debbia EA; Schito GC; Russo G Drugs Exp Clin Res; 1989; 15(3):119-23. PubMed ID: 2752910 [TBL] [Abstract][Full Text] [Related]
16. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569 [TBL] [Abstract][Full Text] [Related]
17. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections]. Mróz E; Jankowski S; Bartelmus J; Grzybek-Hryncewicz K; Ruczkowska J; Starek J; Boratyńska M Med Dosw Mikrobiol; 1993; 45(1):115-8. PubMed ID: 8231429 [TBL] [Abstract][Full Text] [Related]
18. [In vitro fluoroquinolone resistance in ocular bacterial isolates]. Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574 [TBL] [Abstract][Full Text] [Related]
19. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139 [TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates. Periti P; Mazzei T; Nicoletti P Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]